Scientific poster - Comparing CSF and plasma LUMIPULSE® Alzheimer’s Disease biomarker analysis to amyloid-β PET imaging

Mar 16, 2022

Poster presented on March 16, 2022 at the AD/PD™ 2022

Amyloid pathology-confirmed diagnosis of Alzheimer’s Disease has been an increasing area of focus.  Assistance of diagnosis using amyloid PET imaging or cerebrospinal fluid biomarkers has been challenging to implement in clinical care due to cost, availability, and/or invasiveness of sampling.  These hurdles can be circumvented by the assessment of biomarkers in the more easily accessible plasma.

The aim of this study was to evaluate a plasma pTau biomarker as a tool for predicting amyloid pathology.

Download poster

Subscribe to Fujirebio insight updates

Get all the latest insight articles from Fujirebio the moment they are published.

The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

Related articles

Related products

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.